Description
(AWP Alliance News) - Coloplast outlined revised 2030 financial targets at its Nov. 3, 2026, fourth-quarter earnings call, attended by CEO Gavin Wood, CFO Anders Lonning-Skovgaard and analysts. Management now targets annual organic growth of 5% 7% through fiscal 2029/2030, with an EBIT margin in constant currencies in the mid-20s.
The revision reflects healthcare pricing pressure, inflation and US outpatient reimbursement changes, alongside increased investment in innovation and US growth. For fiscal 2026/2027, management forecasts organic growth of 5% 7% and an EBIT margin of around 25%, with a slower first quarter as reimbursement changes continue to weigh on Biologics.
Its resource-reallocation program targets DKK 500 million, with 75% of the benefit expected during the year; about 80% will fund stepped-up investment.
https://docs.publicnow.com/427067166F9FE3B8EE4264AE9227C9327E5D8BCB
Disclaimer: This news brief was created using generative artificial intelligence. Coloplast A/S published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.
